MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/92.5/0.1/21.06.24

MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/92.5/0.1/21.06.24 Share Price

DE000MB29066

Delayed Börse Stuttgart 12:18:19 01/06/2024 am IST
0.007 ^EUR	+16.67%

3 months	-12.50%
6 months	-56.25%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ASTRAZENECA PLC

Chart MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/92.5/0.1/21.06.24

Latest news about ASTRAZENECA PLC

Presage Biosciences Announces New Pharma Partnership to Evaluate Novel Immuno-Oncology Drug Combinations with CIVO® Technology	30/11	PR
New analysis of Phase II data at AACR assesses ImaginAb's investigational CD8 ImmunoPET technology's ability to predict response in immunotherapy	14/23/14	PR
Invitae Announces Partnership for Real-World Data Sharing to Inform Rare Cancer Research	27/22/27	PR
Baili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 bispecific Antibody, in Combination with Tagrisso® in Patients with Non-Small Cell Lung Cancer	14/22/14	PR

More news

Quotes 5-day view

Date	Price	Change
31/24/31	0.007	+16.67%
30/24/30	0.006	-.--%
29/24/29	0.006	+500.00%
28/24/28	0.001	-.--%
27/24/27	0.001	-85.71%

Delayed Quote Börse Stuttgart

Last update May 01, 2024 at 12:18 am IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	ASTRAZENECA PLC
Issuer	Morgan Stanley
WKN	MB2906
ISIN	DE000MB29066
Date issued	11/01/2023
Strike	92.5 $
Maturity	21/06/2024 (18 Days)
Parity	10 : 1
Emission price	0.37 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	0.27 €
Lowest since issue	0.001 €
Delta	0x
Omega	0.000000
Premium	0x
Gearing	0x
Moneyness	0.8435
Difference Strike	13.67 $
Difference Strike %	+14.78%
Intrinsic value	0.000000

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

More about the company

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: AstraZeneca PLC

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

155.1 USD

Average target price

172 USD

Spread / Average Target

+10.91%

Consensus